GT Biopharma (GTBP) Interest Coverage Ratio (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Interest Coverage Ratio of 45.21 for Q1 2026, down 1725.1% year-over-year from 2.78 in Q1 2025, and down 10322.91% quarter-over-quarter from 0.43 in Q4 2025.
GT Biopharma (GTBP) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Interest Coverage Ratio for 17 consecutive years, with 45.21 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 1725.1% year-over-year to 45.21; the TTM figure through Mar 2026 stood at 48.5 (down 186.46% YoY), while the FY2025 annual figure was 0.09, up 31.25% from the prior year.
- Interest Coverage Ratio fell to 45.21 in Q1 2026 per GTBP's latest filing, from 0.43 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.01 in Q2 2022 and bottomed at 103033.33 in Q1 2024.
- Historically, Interest Coverage Ratio has averaged 7368.75 across 5 years, with a median of 1.46 in 2025.
- Annual changes were most pronounced in 2024 — Interest Coverage Ratio sank 595890.9% — and 2025, when it surged 100.0%.
- GT Biopharma's Interest Coverage Ratio stood at 0.05 in 2022, then sank by 63870.41% to 33.93 in 2023, then jumped by 99.9% to 0.03 in 2024, then slumped by 1193.03% to 0.43 in 2025, then sank by 10322.91% to 45.21 in 2026.
- Business Quant data shows GTBP's Interest Coverage Ratio at 45.21 in Q1 2026, 0.43 in Q4 2025, and 12.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | -45.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.21 |
| Dec 31, 2025 | -0.43 |
| Sep 30, 2025 | -12.04 |
| Jun 30, 2025 | -0.06 |
| Mar 31, 2025 | -2.48 |
| Dec 31, 2024 | -0.03 |
| Mar 31, 2024 | -103,033.33 |
| Sep 30, 2023 | -33.93 |
| Jun 30, 2023 | -17.00 |
| Mar 31, 2023 | -17.29 |
| Dec 31, 2022 | -0.05 |
| Sep 30, 2022 | -0.37 |
| Jun 30, 2022 | -0.01 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -826.27 |
| Mar 31, 2021 | -41.67 |
| Dec 31, 2020 | -1.88 |
| Sep 30, 2020 | -2.09 |
| Jun 30, 2020 | -0.10 |
| Mar 31, 2020 | 1.68 |